Preservative-free Ganfort formulation gains marketing authorization for glaucoma in EU

A preservative-free, single-dose formulation of Ganfort ophthalmic solution has been granted marketing authorization covering all 27 European Union countries by the European Medicines Agency, according to a news release.Ganfort (bimatoprost 0.03% / timolol 0.5%, Allergan) is indicated for reduction of IOP in patients with open-angle glaucoma or ocular hypertension that is insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Full Story →